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Abstract: Cytomegalovirus (CMV) is the leading cause of congenital infection. Its occurrence is
phenotypically heterogeneous. The type of maternal infection, primary or non-primary, is an important
factor related to the symptomatic disease, the primary infection was long considered the only cause
of severe neonatal disease. We aimed to analyze the association of primary and non-primary
infection with pathological outcomes in infants and with long-term sequelae at follow-up. This was
a monocentric retrospective observational study on a population of 91 infants diagnosed with a CMV
infection at the Neonatal Care Unit of Neonatology at the Sant’Anna Hospital of Turin during the
period of June 2005 to December 2018. Infants underwent clinical, laboratory, and neuroradiological
evaluations at birth. Subsequently, the patients were monitored in an auxological, neurodevelopment,
and audiological follow-up. Regarding primary vs. non-primary infection, we found a higher
percentage of incidence of symptomatic and neurological localized infection, as well as long-term
sequelae in the latter. However, no significant difference between the two populations was found.
We underline the possibility of re-infection in previously immunized mothers (non-primary infection)
with unfavorable neonatal and long-term outcomes.
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1. Introduction
Cytomegalovirus (CMV) is the leading cause of congenital infection, affecting 0.5%–5% of live
births worldwide [1]. Since CMV can cause severe auditory and neurobehavioral sequelae, it has
an important impact on global health. In Italy, the prevalence of congenital cytomegalovirus (cCMV)
infection is among the lowest in the literature and it varies between 0.15% in children born to women
over 24 years of age and 0.51% of women below this age [2]. cCMV is a pathology with large phenotypic
variability that manifests with a wide variety of signs and symptoms; the infected newborn can be
either completely asymptomatic or show alterations of laboratory tests or display numerous symptoms
from pathologies of the gastrointestinal tract and spleen up to neurological and cognitive disabilities.
cCMV represents one of the main causes of sensorineural hearing loss (SNHL) [3].
The underlying causes of this variability are not yet fully known. One of the main variables is
the trimester of infection as the main phase at risk for the development of neurological sequelae in
infected infants [4]. When accurately determined, the type of infection enables defining the risk of its
transmission to the fetus and, importantly, estimating the severity of the disease that can be assessed
both as a symptom upon birth and as a long-term outcome. For a long time, primary maternal infections
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were assumed to have a more significant global clinical impact than non-primary infections [5,6];
however, more recent studies confirmed that congenital infections are also detected in newborns born
from mothers with previous immunity. Maternal immunity does not seem to be protective neither
in terms of preventing the transmission of the virus to the fetus nor in terms of the severity of the
infection itself [7–9].
For these reasons, universal CMV screening of pregnant women is not recommended according
to the latest consensus recommendations [3]. In the absence of a valid vaccine and with many vaccine
candidates currently under development, the only means of prevention are hygiene measures [10].
Given the growing evidence of the relevance of non-primary infection, these measures should be
directed to all pregnant women, both seronegative and seropositive [11].
The aim of our study was to analyze the association of primary and non-primary infection with
pathological outcomes in infants with auxological, neurodevelopmental, and audiological sequelae at
the follow-up to ensure appropriate evaluation of CMV risk in these subjects.
2. Materials and Methods
2.1. Study Design and Population Selection
This monocentric retrospective observational study was comprised of a population of 91 newborns
diagnosed with congenital CMV infection enrolled at the Neonatal Care Unit of Sant’Anna University
Hospital of Turin from June 2005 to December 2018. Ethics approval was provided on 8 April 2019 by
the Ethical Committee of the City of Health and Science Hospital of Turin (Italy), protocol number
0041678. Informed consent was obtained from the parents of the children recruited into this study.
2.2. Study Population
Congenital CMV (cCMV) infection was confirmed based either on detection of CMV DNA in
urine samples collected within the 21st day of life or on viral DNA detection on a Guthrie Card after
the 21st day of life [12,13]. Symptomatic cCMV infection was defined if one or more of the following
signs or symptoms were present: hematologic (thrombocytopenia, petechiae, splenomegaly), hepatic
(hepatomegaly, hepatitis—defined as elevated transaminases or prolonged jaundice and/or elevated
conjugated bilirubinaemia), auxological (small for gestational age (SGA)–defined as a birthweight
<10th percentile compared to gestational age curves, microcephaly—defined as head circumference
<3rd percentile compared to gestational age curves [14]), neurological (chorioretinitis, sensorineural
hearing loss (SNHL), lethargy, convulsive crisis), ultrasound (US) abnormalities (ventriculomegaly,
cysts, vasculitic striae, brain calcifications), and magnetic resonance imaging (MRI) abnormalities
(cysts, myelination delay, ventriculomegaly, changes in the corpus callosum, hemispherical and/or
cerebellar asymmetries, alterations of auditory courting).
In each case of this study, the data on the maternal infection were analyzed. Primary infection was
defined as a seroconversion in pregnancy in previously seronegative women. We were able to date the
trimester of infection by identifying the date of maternal seroconversion. Otherwise, non-primary
infection was defined as a re-infection in previously seropositive women. In this case, tracing the
history of maternal suggestive symptoms during pregnancy and fetal abnormalities enabled us to
identify the trimester of infection.
2.3. Follow-Up
After discharge, patients underwent follow-up visits to evaluate the evolution of the pathologies.
Auxological, neurodevelopmental, and audiological follow-up was performed. Follow-up lasted
12 months for asymptomatic infants with an asymptomatic disease course and 24 months for both
symptomatic infants and those who manifested abnormalities during follow-up.
As part of the auxological follow-up, the weight, length, and head circumference parameters were
measured during each visit. The measurements were then plotted to the corresponding Centers for
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Disease Control and Prevention (CDC) growth charts and the centiles were calculated [15]. The weight
values under the 3◦ centile on CDC curves divided for age and sex at the last visit performed were
defined as a display of auxological impairment.
Neurodevelopmental follow-up was performed using the Griffiths Mental Development Scale II.
At the end of the evaluation, the General Quotient was obtained. In our study, a General Quotient <85
was considered as neurodevelopmental delay.
Evaluations of the audiological follow-up were performed at the first, second, third, and sixth
audiological visits. The subject was diagnosed as hypoacusic when presented with auditory brainstem
response (ABR) values >30 or auditory steady state response (ASSR) values >30, separately for each
ear. Indication of the need for cochlear implant, used as a proxy of bilateral severe SNHL, at the end of
the audiological follow-up period was also determined as a long-term outcome.
2.4. Statistical Analysis
A statistical analysis was performed using R (www.r-project.org). Results for continuous variables
are provided as means and standard deviation. Results for factorial variables are given as numbers
and percentages. The categorical variables between groups were compared using a series of Fisher’s
exact tests. Values of p < 0.5 were considered statistically significant.
3. Results
Of the 91 children diagnosed with congenital CMV infection, 41 women (45%) and 50 men
(55%) were enrolled in the present study. The baseline characteristics of our selected population are
summarized in Table 1.
Table 1. Baseline characteristics.
Birth N = 48
Eutocic 26 (53%)
Cesarean 23 (47%)
Gestational Age N = 90
37.9 (±1.94)
Apgar 5′ ≥ 7 * N = 50
50 (100%)
Birth weight N = 89
2786 ± 658 g
Birth head circumference N = 89
33 ± 2.2 cm
* Apgar score: Evaluation of the heart rate, muscle tone, grimace, color, and breathing in the first minutes of life.
A score of 7 to 10 after 5′ is considered normal.
Regarding the trimester of cCMV infection during pregnancy, the following values were obtained:
the data on 39 patients were missing, whereas the determined cases accounted for 40% of patients
infected in the first trimester, 29% in the second trimester, and 16% in the third, accordingly. The data
regarding the type of infection were distributed as follows: the data on 42 patients were missing,
the determined cases included 86% of patients with primary infection and 14% with non-primary
infection. The characteristics of maternal infection are summarized in Table 2.
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Table 2. Characteristic of maternal infection.
Infection Diagnosis N = 71
Not detected in pregnancy 17 (24%)
Targeted screening 35 (49%)
Intrauterine growth restriction (IUGR) 4 (6%)
Fetal ultrasonography abnormalities (non-IUGR) 3 (4%)
Flu-like syndrome 12 (17%)
Trimester of Infection N = 52
I 21 (40%)
II 15 (29%)
III 16 (31%)
Type of Infection N = 49
Primary 42 (86%)
Non-primary 7 (14%)
Characteristics of fetal abnormalities and symptoms of infection detected at birth are summarized
in Table 3.
Table 3. Fetal and neonatal infection features.
Fetal Ultrasonography Abnormalities N = 91
Not specified 6 (7%)
Ventriculomegaly 4 (4%)
Frontal cyst 1 (1%)
IUGR 12 (23%)
Signs at Birth N = 91
Small for Gestational Age (SGA) 35 (40%)
Thrombocytopenia 5 (9%)
Neutropenia 11 (19%)
Impaired liver function 9 (17%)
Aspartate Aminotransferase/Alanine
Aminotransferase
(AST/ALT) Alteration
10 (19%)
Gamma-Glutamyl Transpeptidase
(GGT) Alteration 20 (37%)
Petechiae 1 (1%)
Hepatomegaly 3 (4%)
Splenomegaly 2 (3%)
Chorioretinitis 1 (1%)
Seizures 0
Lethargy 0
Altered audiological screening 14 (17%)
Altered Brain Ultrasound 48 (56%)
Altered Brain Magnetic Resonance 19 (37%)
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Considering data of neurodevelopmental, auxological and audiological follow-up, simplified in
binomial variables, the percentages concerning the long-term sequelae driven by cCMV were calculated.
While the auxological delay has been reported in 25% of children, 31% displayed neurodevelopmental
impairment, 21% displayed hearing loss, and 9% of patients indicated a need for cochlear implantation
used as a proxy of severe bilateral SNHL.
When analyzing the different occurrences in the first trimester vs. the second and third trimesters
of infection, we found that in the first trimester, the occurrence of a symptomatic infection at birth
accounted for 81% vs. 66% in the other trimesters and with no significant difference in the two groups
(p = 0.346). However, the occurrence of a neurologically symptomatic infection was 75% vs. 40%
(p = 0.021). Regarding long-term follow-up, we found that in the first trimester, the occurrence of need
for a cochlear implant was 28% vs. 0% (p = 0.003). Other data on the differences between the two
patients’ groups are summarized in Table 4.
Table 4. Differences between trimester.
Outcomes In (%)
II/III
n (%) p-Value
Symptomatic infection 17 (81) 20 (66) 0.346
Neurological localized infection 15 (75) 12 (40) 0.021
Auxological Impairment 5 (28) 4 (18) 0.705
Neurodevelopmental impairment 4 (23) 2 (9) 0.373
Hearing Loss 7 (33) 3 (12) 0.149
Need for cochlear implant 6 (28) 0 0.003
Particular attention was paid to the non-primary infection and its incidence in symptomatic
cases in this patients’ group is reported in Table 5. No significant differences between the two groups
were found.
Table 5. Differences between the two types of infection.
Outcomes Primaryn (%)
Non-Primary
n (%) p-Value
Symptomatic infection 30 (71) 6 (85) 0.658
Neurological localized infection 22 (54) 6 (85) 0.214
Auxological Impairment 9 (28) 2 (29) 1
Neurodevelopmental impairment 5 (15) 1 (20) 1
Hearing Loss 9 (24) 3 (50) 0.325
Need for cochlear implant 4 (10) 3 (43) 0.05
Finally, in Table 6, we report the series of our cases of infants affected by cCMV after maternal
non-primary infection.
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Table 6. Non primary infection.
Case Trimester of infection Outcomes
1 I
Severe bilateral Sensorineural Hearing Loss
(SNHL); cyst on brain ultrasound (US) and
MRI; Neurodevelopmental impairment
2 NA SGA, cyst on brain US
3 I
Fetal US abnormalities, thrombocytopenia,
widespread hyperechogenicity and
germinal matrix hemorrhage on brain US
4 I Asymptomatic
5 I
Fetal US abnormalities (ventriculomegaly),
widespread hyperechogenicity and
ventriculomegaly on brain US; cyst, delayed
myelination, and ventriculomegaly on MR;
macular abnormalities on fundus oculi and
fluctuating severe SNHL
6 NA IUGR, SGA, microcephaly, widespreadhyperechogenicity on brain US
7 NA IUGR, SGA, microcephaly, severe bilateralSNHL, cyst on brain US
4. Discussion
Cytomegalovirus is the leading cause of congenital infection worldwide and it represents
an important global health burden. Considering the extreme variability of disease manifestations,
identifying congenital CMV infection at risk implies a significant step toward the improvement of the
patients’ management, treatment, and follow-up.
In this retrospective observational study, we analyzed auxological, neurodevelopmental,
and audiological follow-up outcomes of infants diagnosed with congenital CMV to improve the
understanding of the clinical course of the infection, as well as to identify the factors defining what
population may appear most at risk of presenting the CMV disease.
The data regarding the trimester of infection demonstrated that the infants whose mothers were
infected during the first trimester presented neurological signs more often (75% vs. 40% (p = 0.021)).
These results are in line with those reported in the literature [1], highlighting the actual need to diagnose
and to keep the first trimester infections under strict control. We point out the significant difference in
the incidence of the indication of a need for a cochlear implant in the two population groups: 28% in
the first trimester and 0% in the others (p = 0.019), suggesting that severe bilateral SNHL is limited only
in the former. In our study, we focused on outcomes within the first/second year of life, the most critical
periods for the child neurodevelopment. Aware of the possibility of late-onset SNHL [16,17], it would
be interesting to analyze, in further works, how many of these children have a need for belated hearing
aid repair.
Considering the differences in the type of infection analyzed (primary vs. non-primary),
the percentage of symptomatic cases at birth was 71% for primary and 85% for non-primary patients,
whereas neurological localization was reported in 54% of primary and 85% of non-primary cases.
The same tendency was observed for long-term sequelae, in which the non-primary infection appeared
to have an increased risk of unfavorable auxological, neurodevelopmental, and audiological outcomes.
No significant differences were found between the two patients’ groups. However, these last results
may be explained by the group of patients with primary infection being composed of 42 individuals,
whereas the non-primary group included seven individuals, implying a low statistical significance.
Notably, the data on the type of CMV infection were missing 42 patients out of 91. This was due
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to the absence of universal screening in pregnancy. Thus, it is often impossible to trace the exact
characteristics of maternal infection.
Although our study design did not allow us to provide essential epidemiological information,
our results showed that non-primary CMV infection must not be underestimated even though the
percentages found are unlikely to be generalized to the entire population. In this type of infection,
we mostly likely only diagnosed and selected infants with pathologies and, therefore, missed the
diagnosis of the asymptomatic ones. For patients with a primary infection, we obtained a significant
heterogeneous cohort.
The presence of cases with important clinical sequelae in a subgroup of children born to mothers
with previous immunity to CMV, for which we underline the incidence of the need for a cochlear
implant, contradicts the reported cases in the literature. Thus, highlighting this type of infection as
of particular importance in diagnostics and clinical management supporting the opinion of several
authors that non-primary CMV infection is at least as serious as a primary infection [7–9]. Consequently,
prevention measures should also be extended to seropositive mothers and particular attention must be
paid to all early signs of prenatal and neonatal CMV infection in these infants.
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